Impact of age at diagnosis of de novo metastatic prostate cancer on survival

An older age at the diagnosis of prostate cancer has been linked to worse prostate cancer–specific survival (PCSS). However, these studies were conducted before the approval of many life‐prolonging drugs. This study was aimed at describing outcomes in a contemporary cohort of men diagnosed with de novo metastatic prostate cancer (mPCa) and assessing associations with the age at diagnosis while controlling for known prognostic factors.

[1]  K. Gupta,et al.  Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease , 2017, Clinical genitourinary cancer.

[2]  R. deVere White,et al.  No improvement noted in overall or cause‐specific survival for men presenting with metastatic prostate cancer over a 20‐year period , 2014, Cancer.

[3]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[4]  W. DeWolf,et al.  Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance , 2014, BJU international.

[5]  J. Snowden,et al.  Comprehensive geriatric assessment and decision-making in older men with incurable but manageable (chronic) cancer , 2018, Supportive Care in Cancer.

[6]  E. Messing,et al.  Prostate cancer in the elderly , 2012, Cancer.

[7]  K. Do,et al.  Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy , 2006, Cancer.

[8]  C. Radulescu,et al.  Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading , 2015, Prostate Cancer and Prostatic Disease.

[9]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Owens,et al.  Annual Report to the Nation on the status of cancer, part II: Recent changes in prostate cancer trends and disease characteristics , 2018, Cancer.

[11]  S. Mohile,et al.  How we treat early systemic prostate cancer in older men. , 2014, Journal of geriatric oncology.

[12]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[13]  V. Conteduca,et al.  Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. , 2016, Clinical genitourinary cancer.

[14]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[15]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[16]  F. Saad,et al.  Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. , 2014, European urology.

[17]  A. Pereira,et al.  Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer , 2017, Journal of global oncology.

[18]  J. Beilby,et al.  Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25–84 Years from the Busselton Health Study , 2018, Hormones and Cancer.

[19]  N. Lumen,et al.  Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. , 2018, Urologic oncology.

[20]  A. Scarpa,et al.  Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer , 2018, Targeted Oncology.

[21]  M. Humphreys,et al.  Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC) , 2013, Journal of Cancer.

[22]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[23]  I. Derweesh,et al.  Survival outcomes in men receiving androgen‐deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20‐year single‐centre experience , 2009, BJU international.

[24]  S. Morita,et al.  Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer , 2015, BMC Cancer.

[25]  R. A’Hern.  Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Sugihara,et al.  Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. , 2014, The Lancet. Oncology.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  T. Beer,et al.  Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents , 2014, Drugs & Aging.

[29]  Jennifer R. Rider,et al.  Restricted Mean Survival Times to Improve Communication of Evidence from Cancer Randomized Trials and Observational Studies. , 2019, European urology.

[30]  S. Culine,et al.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.

[31]  Karel G M Moons,et al.  Missing covariate data in clinical research: when and when not to use the missing-indicator method for analysis , 2012, Canadian Medical Association Journal.

[32]  M. Kattan,et al.  Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer , 2016, Front. Oncol..

[33]  T. Choueiri,et al.  Association Between Older Age and Increasing Gleason Score. , 2015, Clinical genitourinary cancer.

[34]  P. Royston,et al.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt , 2011, Statistics in medicine.

[35]  Eric J Feuer,et al.  Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics , 2018, Cancer.

[36]  Sander Greenland,et al.  Theoretical Epidemiology: Principles of Occurrence Research in Medicine , 1986 .